Observed/expected, standardised incidence ratios (SIR) (95% CIs) white and black men
| Type of malignancy |
Observed/ Expected | SIR (95% CI) |
| All malignant neoplasms4-150 | 637/656.84 | 0.97 (0.90 to 1.05) |
| Malignant neoplasms of lymphatic and haematopoietic tissue (200–208) | 55/46.56 | 1.18 (0.89 to 1.54) |
| Hodgkin's disease (201.0–201.9) | 4/2.59 | — |
| Non-Hodgkin's lymphoma4-151 (NHL) (200.0, 200.1, 200.2, 200.8, 202.0, 202.1, 202.2, 202.8, 202.9) | 22/20.64 | 1.06 (0.67 to 1.61) |
| Reticulosarcoma (200.0) | 5/4.46 | 1.12 (0.36 to 2.62) |
| Lymphosarcoma (200.1) | 3/3.81 | — |
| Burkitt's lymphoma (200.2) | 0/0.06 | — |
| Other named variants (200.8) | 7/3.59 | 1.95 (0.78 to 4.02) |
| Nodular or follicular (202.0) | 5/3.13 | 1.60 (0.51 to 3.73) |
| T-cell lymphoid (202.1-mycosis fungoides, 202.2-Sezary's disease) | 1/0.33 | — |
| Other lymphomas (202.8) | 1/5.20 | 0.19 (0.005 to 1.07) |
| Multiple myeloma (203.0) | 9/6.48 | 1.39 (0.64 to 2.64) |
| Leukaemia (204–208) | 17/13.16 | 1.29 (0.75 to 2.07) |
| ANLL (205.0, 206.0, 207.0, 207.2) | 4/4.22 | — |
| CML (205.1) | 4/2.21 | — |
| ALL (204.0) | 2/0.67 | — |
| CLL (204.1) | 5/4.10 | 1.22 (0.40 to 2.85) |
| Other and unspecified leukaemia (204.2, 204.8, 204.9, 205.2, 205.3, 205.8, 205.9, 206.1, 206.2, 206.8, 206.9, 207.1, 207.8, 208.0, 208.1, 208.2, 208.8, 208.9 | 2/1.96 | — |
| Lymphohaematopoietic malignancies not in main groupings (202.3–202.6, 203.1, 203.8)4-152 | 3/0.70 | — |
| B-cell (202.4 hairy cell leukaemia), 203.1 plasma cell leukaemia) | 2/0.38 | — |
| Other (202.3, 202.5, 202.6, 203.8) | 1/0.32 | — |
↵4-150 All analyses consider multiple primaries (see methods text). SIRs are calculated only if there are at least five observed cases or five expected.
↵4-151 NHL is defined according to the SEER ICD-0-2 codes, which includes morphology codes M9590-9595 and M9670-9715 (all sites). These codes were converted to the ICD-9 codes listed in the table.
↵4-152 These conditions are not part of the lymphoma, leukaemia, or multiple myeloma categories defined in this study (see methods text).